Caplacizumab: caplacizumab, a humanized immunoglobulin originally from llamas, targeting the A1 domain of VWF and thereby preventing its interaction with platelets is the first medication approved specifically to treat TTP. This evidence concerns the gene VWF and thrombotic thrombocytopenic purpura.